BCR and chronic myelogenous leukemia, BCR-ABL1 positive: After initial approval in 2021, the US asciminib product label was recently updated; asciminib received accelerated approval for adults with newly diagnosed Philadelphia chromosome–positive (Ph + ) CML-CP, supported by results from the ASC4FIRST trial, and full approval for adults with Ph+ CML-CP that is previously treated or who have BCR::ABL1T315I, supported by the current phase 1 and ASCEMBL trials [15, 16, 25, 26, 30–32].